66
Participants
Start Date
May 23, 2024
Primary Completion Date
December 31, 2026
Study Completion Date
January 31, 2027
Debio 4228
Administered as IM injection.
RECRUITING
AZ Groeninge, Kortrijk
RECRUITING
AZ Delta, Roeselare
NOT_YET_RECRUITING
University Hospital Gent, Ghent
RECRUITING
New York Cancer and Blood Specialists, Shirley
RECRUITING
Urology of Virginia, Virginia Beach
RECRUITING
Associated Urologists of North Carolina, Raleigh
RECRUITING
Hospital Clinico San Carlos, Madroñera
NOT_YET_RECRUITING
CHRU de Brest - Hopital Morvan, Brest
RECRUITING
Carolina Urologic Research Center, Myrtle Beach
RECRUITING
AP Medical Research, Miami
RECRUITING
Biogenix Molecular, Miami
RECRUITING
CHU de Nantes - Hôtel Dieu, Nantes
RECRUITING
Instituto Valenciano de Oncologia, Valencia
RECRUITING
First Urology- Jeffersonville, Jeffersonville
NOT_YET_RECRUITING
CHU Angers, Angers
RECRUITING
Centre Jean Perrin, Clermont-Ferrand
RECRUITING
GU Research Network/Wichita Urology Group, Wichita
RECRUITING
Urology Clinics of North Texas, Dallas
NOT_YET_RECRUITING
East Valley Urology Center of Arizona, Queen Creek
NOT_YET_RECRUITING
Urologic Surgeons of Arizona, Mesa
NOT_YET_RECRUITING
Urology Group of Southern California, Los Angeles
COMPLETED
Advanced Urology, Los Angeles
RECRUITING
Tower Urology,, Los Angeles
NOT_YET_RECRUITING
Alarcon Urology Center, Montebello
NOT_YET_RECRUITING
Pasadena Urological Medical Group, Pasadena
NOT_YET_RECRUITING
Grimaldi Urology, Chula Vista
RECRUITING
Urology Center of Southern California, Murrieta
RECRUITING
Bakersfield Institute of Advanced Urology, Bakersfield
RECRUITING
Valley Urology, Fresno
RECRUITING
Oregon Urology Institut, Springfield
RECRUITING
Summit Cancer Centers of North Spokane, Spokane
RECRUITING
Hospital Universitario Vall d'Hebron, Barcelona
RECRUITING
Corporacio Sanitaria Parc Tauli - Hospital de Sabadell, Sabadell
Lead Sponsor
Debiopharm International SA
INDUSTRY